Huge variations between countries in time for reimbursement decisions on new cancer drugs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Some European countries take more than twice as long as others to reach health technology assessment decisions to reimburse new cancer drugs following their approval by the European Medicines Agency.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login